How to access Onpattro from Saudi Arabia — the named-patient import pathway, 2026

By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23

A Saudi patient diagnosed with hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy may receive a prescription for Onpattro (patisiran) from their treating neurologist, often working alongside cardiology in a multidisciplinary amyloid clinic at a Riyadh, Jeddah, or Eastern Province tertiary centre. Onpattro is FDA-approved for this indication and developed by Alnylam Pharmaceuticals. Routine stocking through Saudi hospital pharmacies for this indication is inconsistent, which is why named-patient import through the Saudi Food and Drug Authority (SFDA) is the typical route when a neurologist determines the therapy is clinically indicated.

This guide explains the legal pathway, the documentation your physician prepares, typical timing, indicative cost posture, and where Reserve Meds fits in.

The clinical situation

Onpattro is a lipid-nanoparticle-encapsulated siRNA that silences hepatic TTR production. It is administered by intravenous infusion every three weeks, preceded by an on-label premedication regimen — a corticosteroid, an H1 and H2 antihistamine, and acetaminophen — to reduce infusion-related reactions. Eligibility requires genetic confirmation of a pathogenic TTR variant, symptomatic polyneuropathy, and a cardiac workup to characterise any ATTR-CM overlap. Your neurologist will establish baseline neuropathy impairment scoring (NIS+7), polyneuropathy disability score, quality-of-life measures, and identify an infusion-capable clinic. Compared with subcutaneous siRNA options like Amvuttra, Onpattro requires infusion infrastructure and the premedication routine — a consideration your neurologist weighs with you and your family.

Is Onpattro legally importable into Saudi Arabia?

Yes — through the SFDA named-patient import framework. The SFDA named-patient route allows a Saudi-licensed physician to request import of a medicine not locally registered when (a) the medicine has been approved by a recognised reference authority such as the US FDA, (b) no clinically equivalent locally registered alternative suits the patient, (c) the treating physician takes clinical responsibility for use, and (d) the importing party documents chain of custody from the US source to the administering facility. hATTR polyneuropathy has limited disease-specific registered alternatives, which supports clinical rationale.

How the pathway works, step by step

1. Consultation with your treating neurologist. TTR genetic report, neuropathy scoring, and a clinical rationale letter documenting the absence of equivalent registered alternatives.
2. Baseline assessment. NIS+7, polyneuropathy disability score, cardiac workup (ECG, echocardiogram, NT-proBNP), and identification of an infusion-capable clinic.
3. SFDA named-patient application. The physician or hospital pharmacy files clinical rationale, patient reference, dosing and premedication plan, and chain-of-custody commitment.
4. US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure Onpattro from authorised distribution under DSCSA.
5. Cold-chain shipment. Onpattro is a refrigerated product; shipment follows validated cold-chain protocols with temperature logging.
6. Arrival and infusion. The hospital pharmacy receives the vial; the infusion centre administers the dose with the on-label premedication regimen.

What documentation your physician needs

• Clinical rationale letter confirming hATTR polyneuropathy and Onpattro as the indicated therapy
• Verification of Saudi medical licence (SCFHS / MOH)
• TTR genetic test result
• Baseline NIS+7 and polyneuropathy disability score
• Cardiac assessment for ATTR-CM overlap
• Planned infusion schedule (every 3 weeks) and premedication regimen
• Infusion-centre identification and accreditation

Reserve Meds provides a physician documentation kit bundling the templates SFDA reviewers expect for rare-disease neurology named-patient imports.

Costs and timing

Onpattro for hATTR polyneuropathy is a substantial rare-disease therapy. Reference US cash-pay for a full annual course (every-three-week infusions) typically sits in the mid-to-high six-figure USD range. Reserve Meds operates on a drug-only reference basis and provides a transparent, itemised delivered quote — covering product, cold-chain logistics, SFDA documentation handling, customs clearance, and concierge coordination — at the start of intake. Figures are indicative, not a binding quote until intake is complete.

Indicative timing — not guaranteed — for first dispense after cohort intake opens is approximately 7–14 days from the moment a complete SFDA application is submitted. The every-three-week infusion cadence is then scheduled with the infusion centre.

Reserve Meds is in pre-launch. Fulfillment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, flag that when you join the waitlist — we triage accordingly.

A culturally-aware note: Ramadan and Hajj seasons can affect scheduling across Saudi tertiary centres. Our concierge coordinates cycle timing with your family's preferences and your infusion centre's calendar.

Reserve Meds's role

• Sourcing. Through our US-licensed specialty wholesale partner under DSCSA chain-of-custody.
• Documentation. Regulatory package for your physician and SFDA review.
• Logistics. Validated cold-chain shipment to your prescribing hospital pharmacy.
• Concierge case lead. A named point of contact coordinating the infusion cadence.

What we do not do: We are not the prescriber. We do not practise medicine. We are not the dispensing pharmacy. All clinical decisions — including infusion administration — remain with your treating neurologist and the infusion centre. We operate on a waitlist basis during pre-launch.

Frequently asked

Is this legal in Saudi Arabia? Yes, when executed through the SFDA named-patient framework with appropriate documentation. See our trust and compliance page.

How is Onpattro different from Amvuttra? Both are siRNA therapies for hATTR polyneuropathy. Onpattro is intravenous, dosed every three weeks, and requires pre-infusion steroid/antihistamine/paracetamol premedication. Amvuttra is subcutaneous, dosed every three months, and does not require a premedication routine. Your neurologist selects based on clinical picture, infusion-centre access, and patient preference.

Does my centre need infusion capability? Yes — Onpattro is IV-infused with on-label premedication. Your neurologist will confirm an infusion-capable centre before intake.

Will private insurance cover this? Cash-pay is the default. Some Saudi private insurers reimburse named-patient imports on a case-by-case basis; we supply documentation for your submission but do not process insurance claims directly.

Next step — join the first-cohort waitlist

Reserve Meds is opening to a limited first cohort in 2026. Add your case to the waitlist and our concierge case lead will reach out when we enter intake for Onpattro coordination in Saudi Arabia.

Add me to the Onpattro waitlist

Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.

---

Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. We are in pre-launch; service availability is limited to our first cohort and published timelines are indicative, not guarantees. Cash-pay. Export-only (US → overseas). Composite case examples. Not medical advice.

Clinical & regulatory review: Reserve Meds clinical team and AI regulatory-counsel review pipeline. Last medically reviewed: 2026-04-23.